The effect of monovalent copper ions on the suspension of human cells (in vitro)
Medical Research Archives · 2026
DOI: 10.18103/mra.2026.0774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Magal Saphier und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Monovalent copper, Cu(I), is unstable in aerated water, and its effects on mammalian cells are little known. Solutions prepared anaerobically to contain Cu(I) are strongly antibacterial at a nominal concentration of 0.2 mM. Antibacterial activity in solutions with a physiological pH is maintained even after exposure to an air atmosphere for up to one hour; electrochemical tests indicate that the concentration of monovalent copper ions remains high even after one hour in an ambient (room-air) environment. In recent years, the effect of monovalent copper ions on bacteria and fungi has been investigated. The results show a dramatic bacteriocidal and fungicidal effect; 0.2mM of monovalent copper ions can eliminate a population of more than a million bacteria per milliliter at a temperature of 30ºC within minutes. In addition, studies have found a significant effect of monovalent copper ions on enzymes; monovalent copper ions inhibit (non-competitively) enzymes such as DNA polymerase and phosphatase, thus offering a possible explanation for the antibacterial mechanism. In those studies, methods for working with significant concentrations of monovalent copper were developed and applied in this study.
Aim
To describe the effects of such a solution on viability, membrane integrity, cellular metabolic activity, cell detachment, and gap closure in one human cell line.
Methods
Adherent A549 human lung carcinoma cells were exposed to a copper solution prepared by anaerobic reaction of CuCl2 with metallic copper in serum-containing medium with 1% acetonitrile (the Cu(I) preparation; nominal copper 0.02 to 2 mM), or to Cu(II), Ni(II) or Zn(II) at 0.2 mM. Plates were incubated in a standard aerated incubator, and the oxidation state of copper during exposure was not measured. Outcomes were trypan blue exclusion after 7 to 48 hours, reduction of the tetrazolium salt XTT after exposure and 24 hours after removal of the solution, the number of detached cells, and the residual width of a scratch gap over 30 hours.
Results
At 0.2 mM of the Cu(I) preparation, 70% to 79% of the recovered cells excluded trypan blue, compared with 76% to 84% in controls; at 48 hours, the value was 14 percentage points below control, similar to Zn(II) and Cu(II). XTT reduction was undetectable at 0.1, 0.2 and 2 mM, close to control at 0.02 and 0.5 mM and 43% of control at 1 mM, and it did not recover after removal of the solution. Cu(II), Ni(II) and Zn(II) gave 97% to 100% of control. Detached cells were six times as numerous as in the control. The scratch gap was no longer measurable at 30 hours, when 35% of its width remained in controls.
Conclusions
In A549 cells, the Cu(I) preparation at 0.2 mM preserved membrane integrity in most recovered cells but abolished the XTT signal without recovery, increased detachment, and accelerated gap closure in vitro. Thus, the findings indicate that monovalent copper ions at concentrations that extinct microorganisms do not cause the same damage to human cell vitality.
Zitieren
APA
Saphier, M., Saphier, O. I., Moshkovich, L., Lewis, E. C., & Silberstein, E. (2026). The effect of monovalent copper ions on the suspension of human cells (in vitro). Medical Research Archives. https://doi.org/10.18103/mra.2026.0774
Vancouver
Saphier M, Saphier OI, Moshkovich L, Lewis EC, Silberstein E. The effect of monovalent copper ions on the suspension of human cells (in vitro). Medical Research Archives. 2026. doi:10.18103/mra.2026.0774
BibTeX
@article{Saphier2026,
author = {Saphier, Magal and Saphier, Oshra Ilan and Moshkovich, Lea and Lewis, Eli C and Silberstein, Eldad},
title = {The effect of monovalent copper ions on the suspension of human cells (in vitro)},
journal = {Medical Research Archives},
year = {2026},
doi = {10.18103/mra.2026.0774}
}
EUVIMED